Business Context and Reporting Period
Axsome Therapeutics, Inc. filed this Form 8-K on November 8, 2017, to announce financial results for the three months ended September 30, 2017, and to provide an operational update. The Company is a clinical-stage biopharmaceutical firm focused on developing novel therapies for central nervous system disorders and chronic pain.
Financial Metrics
This filing references a press release (Exhibit 99.1) containing the financial results for the three months ended September 30, 2017. The text of this 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for detailed financial data.
Material Changes and Pipeline Updates
The filing details significant progress across three primary product candidates:
- AXS-05 (Bupropion and Dextromethorphan):
- TRD: Enrolling the STRIDE-1 Phase 3 trial for treatment-resistant depression.
- AD Agitation: First patient enrolled in the ADVANCE-1 Phase 2/3 trial in July 2017.
- AXS-02 (Disodium Zoledronate Tetrahydrate):
- CRPS: Enrolling the CREATE-1 Phase 3 trial; approximately 85 subjects randomized as of the filing date. An interim efficacy analysis is expected late December 2017 to early January 2018.
- Knee OA: Evaluating in the COAST-1 Phase 3 trial; an interim sample size analysis is scheduled for the same timeframe as the CRPS interim analysis.
- AXS-06 (MoSEIC Meloxicam and Esomeprazole):
- Received FDA Pre-IND guidance in July 2017.
- Phase 1 pharmacokinetic results showed median Tmax for meloxicam was 9 times faster than commercially available Mobic.
- Management believes the candidate is Phase 3-ready.
Management Commentary, Corporate Updates, and Outlook
Corporate Appointments:
- Cedric O'Gorman, M.D. appointed Senior Vice President, Clinical Development and Medical Affairs (September 2017).
- John Golubieski appointed Chief Financial Officer (effective August 4, 2017).
Anticipated Near-Term Milestones:
- AXS-02 (CRPS & Knee OA): Interim analyses expected late December 2017 to early January 2018.
- AXS-05 (TRD): Top-line data from the STRIDE-1 Phase 3 trial expected in the first half of 2018.
Risks and Contingencies: As a clinical-stage company, the primary risks involve the success of ongoing clinical trials and regulatory approvals. The filing notes that the information provided is not deemed "filed" under Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Verify specific Q3 2017 financial figures (revenue, cash burn, cash on hand) in the attached press release (Exhibit 99.1), as they are not listed in this 8-K text.
- Monitor the interim analysis results for the AXS-02 CRPS and Knee OA trials, expected between late December 2017 and early January 2018.
- Confirm the enrollment status and timeline for the AXS-05 STRIDE-1 Phase 3 trial, with top-line data anticipated in 1H 2018.
- Review the FDA Pre-IND guidance received for AXS-06 to validate the "Phase 3-ready" status.